Human Liver Model Market Size, Share & Trends Analysis Report By Product (2D Models, 3D Models), By Application (ADME Studies, Toxicology Testing), By End-use (Academic & Research Institutes), By Region, And Segment Forecasts, 2024 - 2030

Human Liver Model Market Size & Trends

The global human liver model market size was estimated at USD 1.19 billion in 2023 and is projected to grow at a CAGR of 13.8% from 2024 to 2030. The market is driven by the increasing prevalence of liver diseases, advancements in organ printing technologies, and increased demand for therapeutic drugs for liver cancer, which is expected to propel its growth.

According to the Health Resources & Services Administration, in 2023, in the U.S., 106,800 individuals are waiting for organ transplants. The healthcare landscape is evolving, and advancements in 3D printing technology are set to transform healthcare by addressing organ shortages and improving patient care globally.

The prevalence of liver diseases is on the rise globally, leading to a growing demand for advanced research tools include Human Liver Model. Chronic liver conditions such as non-alcoholic fatty liver disease (NAFLD), alcoholic liver disease, viral hepatitis, and liver cancer are becoming increasingly common due to factors such as unhealthy diets, sedentary lifestyles, alcohol consumption, and viral infections. For instance, NAFLD emerged as the most prevalent chronic liver disorder in Western countries, affecting approximately 25% of the global population. This significant rise in the prevalence of liver diseases has driven the urgent need for more accurate and efficient Human Liver Model to support research and drug development efforts.

Organ 3D printing technologies have advanced significantly recently, particularly in developing Human Liver Model. These advancements have revolutionized regenerative medicine and drug testing by providing more accurate and personalized models for research purposes. For instance, in February 2023, researchers at the University of California San Diego made significant progress in addressing challenging issues in bio printing 3D-engineered tissues, achieving high cell density, viability, and precise fabrication resolution.

Product Insights

The 2D models segment led the market with the largest revenue share of 82.3% in 2023. One key driver is the widespread adoption of 2D models in pharmaceutical research and drug development due to their cost-effectiveness and simplicity compared to more complex 3D models. In addition, the ease of use and well-established protocols for 2D models make them a preferred choice for many researchers. Instances supporting this dominance include the high demand for screening compounds for hepatotoxicity testing, where 2D models are efficient and reliable, leading to their increased utilization in various research applications.

The 3D models segment is expected to witness at the fastest CAGR of 14.9% from 2024 to 2030, due to its ability to closely mimic the complex structure and function of the human liver. These models provide:

• A more accurate representation of in vivo conditions

• Making them valuable tools for drug development

• Disease modelling

• Personalized medicine

For instance, Emulate Inc. offers organs-on-chips technology that recreates the microenvironment of human organs, including the liver, allowing for more precise testing of drug responses and toxicity levels.

Application Insights

Based on application, the ADME (absorption, distribution, metabolism, and excretion) studies segment led the market with the largest revenue share of 39.4% in 2023. The increasing demand for accurate and efficient drug development and testing processes drives this segment. By utilizing Human Liver Model for ADME studies, researchers can simulate human physiological conditions more accurately, leading to better predictions of drug behaviour in humans. As a result, there is a high demand for liver models in the biopharmaceuticals industry which boosts the segment growth.

The toxicology testing segment is projected to exhibit at the fastest CAGR of 14.8% from 2024 to 2030. This can be attributed to the increasing demand for more accurate and predictive in vitro models to assess the safety and efficacy of new drug candidates, chemicals, and cosmetic ingredients. Pharmaceutical and chemical companies are increasingly adopting Human Liver Model, such as 3D bio printed liver tissues and organ-on-a-chip platforms, to replace traditional animal testing methods, which fail to predict human-specific responses accurately. These factors are likely to drive the segment.

End-use Insights

Based on end use, the pharmaceutical & biotechnology segment led the market with the largest revenue share of 48.9% in 2023. This dominance is primarily driven by the increasing demand for advanced liver models for drug development and toxicity testing within these industries. During preclinical studies, pharmaceutical and biotechnology companies rely heavily on Human Liver Model to assess drug metabolism, drug-drug interactions, and hepatotoxicity. Using Human Liver Model allows these companies to enhance the efficiency and accuracy of their drug development processes, leading to cost savings and reduced time-to-market for new pharmaceutical products.

The contract research organizations (CROs) segment is anticipated to witness at the fastest CAGR of 14.5% from 2024 to 2030. The increasing demand for personalized medicine and the rising prevalence of liver diseases propel the need for advanced research and development in this field. CROs offer specialized services and expertise that pharmaceutical companies and research institutions can leverage to accelerate drug discovery processes related to liver diseases.

Regional Insights

North America dominated the human liver model market with the largest revenue share of 41.76% in 2023, due to several unique factors. The region benefits from a robust healthcare infrastructure and favourable regulatory environment that supports the adoption of advanced technologies such as Human Liver Model for preclinical drug testing. North America boasts a high concentration of leading academic research institutions, biotech start-ups, and pharmaceutical companies that drive innovation and collaboration in liver disease research and drug development.

U.S. Human Liver Model Market Trends

The human liver model market in U.S is anticipated to grow at the fastest CAGR during the forecast period. A strong emphasis on personalized medicine and the use of advanced technologies characterizes the U.S. market. The country's healthcare system encourages the adoption of innovative solutions, such as organ-on-a-chip devices, which can simulate the function of human livers. According to CDC, 4.5 million adults aged 18 and older are living with liver disease in the U.S. Hence, the adoption of liver models is expected to increase in this country in the coming years.

Europe Human Liver Model Market Trends

The human liver model market in Europe is witnessing several notable trends. One significant trend is the increasing adoption of advanced technologies such as 3D bio printing and organ-on-a-chip systems for developing more accurate and physiologically relevant liver models. These innovative technologies enable researchers to mimic the complex microenvironment of the liver, leading to improved drug testing and disease modelling capabilities.

Asia Pacific Human Liver Model Market Trends

The human liver model market in Asia Pacific is expected to grow at the fastest CAGR during the forecast period. One significant trend driving this growth is the increasing prevalence of liver diseases in the region, such as hepatitis and liver cancer, which has led to a higher demand for advanced research tools such as Human Liver Model. In addition, the rising investments in healthcare infrastructure and research and development activities in China, Japan, and India fuel the market expansion.

Key Human Liver Model Company Insights

Key players in the global market are pursuing strategic initiatives to bolster their market position. These include collaborations, partnerships, acquisitions, and new product launches. Substantial R&D investments are being made to enhance the capabilities and accuracy of Human Liver Model. These strategies enable companies to diversify their product offerings, improve technological competencies, and address the growing demand for advanced liver models in drug development and toxicology testing.

Recent Developments

• In April 2024, CN Bio secured $21 million in Series B funding to address rising interest in its organ-on-a-chip (OOC) technologies. The initiative is expected to strengthen the company’s market position

• In December 2023, CN Bio introduced its PhysioMimix assay for non-alcoholic steatohepatitis (NASH) to validate the effectiveness of INI-822, a drug developed by Inipharm. This assay is crucial for confirming the drug's efficacy, demonstrating the utility of Organ-on-a-Chip technology in liver disease research and drug development

• In September 2023, UC Davis Health introduced a new program for liver transplants in adults, which enhances the current offerings of the UC Davis Transplant Center and delivers comprehensive care to individuals with liver conditions

Human Liver Model Market Report Scope

Global Human Liver Model Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global human liver model market report based on product, application, end-use, and region:

• Product Outlook (Revenue, USD Million, 2018 - 2030)

  • 2D Models

    • Cell lines

    • Primary Cells

  • 3D Models

    • Liver on Chip

    • Organoids

    • Spheroids

    • Others

• Application Outlook (Revenue, USD Million, 2018 - 2030)

  • ADME Studies

  • Toxicology Testing

  • Disease Modelling

  • Others 

• End-use Outlook (Revenue, USD Million, 2018 - 2030)

  • Academic & Research Institutes

  • Pharmaceutical & Biotechnology Companies

  • Contract Research Organizations

• Regional Outlook (Revenue in USD Million, 2018 - 2030) 

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East and Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait